Zhao Y, Gong P, Chen Y, Nwachukwu JC, Srinivasan S, Ko C, et al
349 Targeting allele-specific compounds Allele-specific compounds that target a single mutant or a group of similar mutants were proposed several decades ago
A separate formulation is used for irrigation such as washing, rinsing and diluting
Cerebrolysin's Position: Decades of clinical use across 40+ countries with established safety and efficacy data Meta-analyses and Cochrane systematic reviews the highest levels of clinical evidence Known limitations: complex mixture makes precise mechanism attribution difficult, not FDA-approved, requires IV/IM administration Represents validated but incrementally effective neurotrophic therapy Dihexa's Position: Exceptional mechanistic novelty HGF/c-Met potentiation at picomolar concentrations is a genuinely unique pharmacological finding if confirmed Entirely preclinical with no human data of any kind Foundational research compromised by expression of concern and retraction the core evidence base is actively questioned Theoretical safety concerns (c-Met oncogenesis) that have not been addressed experimentally Represents frontier neuroscience that has not survived the basic tests of scientific reproducibility For Researchers: Cerebrolysin offers a clinically validated tool for studying neurotrophic effects in humans, supported by the strongest available evidence
The Vitamin C does double duty - it helps with skin lightening and naturally supports collagen, so your skin feels firmer from the inside out
Results Si-based agent showed efficacy in relieving the symptoms of UC To examine whether the Si-based agent prevents the worsening of UC, we generated 5% DSS-induced UC model mice and performed a comparative analysis between the UC model mice fed with 2.5% Si-based agent-containing diets (Si-DSS group) and those fed with diets without the Si-based agent (Con-DSS group)
